TEVA - Teva Pharmaceutical ...About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $8.20 | Open | $8.18 |
| Volume | 15.53M | Market Cap | 9.657B |
| Yield | Last Dividend |
| 2 Warren Buffett Stocks Tumble to 52-Wee... | 3:14 PM |
| Buffett-approved stocks at lower-than-Buffett's prices | |
| Jazz's (JAZZ) New Sleep Drug Sunosi ... | 6:45 AM |
| Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug ... | |
| Pfizer Stock Is The Biggest Pharma — But... | 06/17/19 |
| Pfizer stock has fallen 2% this year, behind pharma stocks. Recent news has been upbeat with a drug approval and earnings beat. But the question remai... | |
| Teva Stock Keeps Sinking Because Opioid ... | 06/17/19 |
| Citi Research analyst Liav Abraham maintained her Buy rating on Teva, but dropped her target price to $13 from $23, and wrote that the company was off... | |
| Teva Pharmaceutical Industries Ltd. (TEV... | 06/13/19 |
| Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.62 in the latest trading session, marking a -1.03% move from the prior day. | |
| The Opioid Epidemic Will Be A Yearslong ... | 06/13/19 |
| Ongoing litigation surrounding the opioid epidemic will be a yearslong overhang for several pharmaceutical companies like Teva Pharmaceutical, Mylan a... | |
| 3 Big Stock Charts for Thursday: H & R B... | 06/13/19 |
| Wednesday's 0.2% setback for the S&P 500 still wasn't enough to push it past the point of no return. But, anything remains possible at this po... | |
| Pharma Giant Nears Two-Decade Low As Opi... | 06/12/19 |
| Teva Pharmaceutical skidded to a nearly two-decade low Wednesday amid confusion over its $85 million payment to Oklahoma to settle an ongoing opioid a... | |
| Teva Retests Lows After Judge Declines S... | 06/12/19 |
| Teva shares briefly reached fresh lows after an Oklahoma judge declined the company's settlement offer and requested more information. | |
| Short Sellers Are Making Bigger Bets Aga... | 06/12/19 |
| Short sellers are taking a growing interest in the specialty pharmaceutical sector as litigation concerns swirl around Teva and Allergan. | |
| Barclays Has New Plays for Healthcare Fa... | 06/12/19 |
| Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are ... | |
| Sell rating | 06/11/19 |
| Barclays initiates coverage with Underweight rating and announces Price Target of $8.00 | |
| Strong Buy rating | 06/03/19 |
| Oppenheimer upgrades from Perform to Outperform rating and announces Price Target of $12.00 | |
| Underperform rating | 05/30/19 |
| Bank of America downgrades from Buy to Underperform rating and lowers Price Target from $19.00 to $9.00 | |
| Hold rating | 05/28/19 |
| UBS downgrades from Buy to Neutral rating and lowers Price Target from $22.00 to $12.00 | |
| Buy rating | 05/09/19 |
| Wells Fargo maintains Market Perform rating and lowers Price Target from $18.00 to $17.00 | |
| Buy rating | 04/11/19 |
| Citigroup maintains Buy rating and lowers Price Target from $27.00 to $23.00 | |
| Buy rating | 04/03/19 |
| Wells Fargo maintains Market Perform rating and lowers Price Target from $20.00 to $18.00 | |
| Buy rating | 03/28/19 |
| BMO Capital initiates coverage with Market Perform rating and announces Price Target of $18.00 | |
| Hold rating | 03/20/19 |
| SunTrust Robinson Humphrey initiates coverage with Hold rating and announces Price Target of $17.00 | |
| Buy rating | 03/07/19 |
| and announces Price Target of $22.00 | |
| Hold rating | 03/06/19 |
| Morgan Stanley downgrades from Overweight to Equal-Weight rating and announces Price Target of $17.00 | |
| Hold rating | 02/14/19 |
| Credit Suisse maintains Neutral rating and lowers Price Target from $26.00 to $20.00 | |
| Hold rating | 01/23/19 |
| PiperJaffray upgrades from Underweight to Neutral rating and raises Price Target from $15.00 to $16.00 | |
| Date | 2019-05-02 (BMO) | Est. (EPS/Rev.) | $0.58/ 4.38B |
| Actual (EPS/Rev.) | $0.60/ $4.30 B | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Trading | Trading | 99.00 % | Follow |
| swing 7% annual | I have traded for 7 years. My goal is 7% annnual return. | 91.00 % | Follow |
| Swing for the fences | Gino Baldassano | 79.00 % | Follow |
| Arbitrage Trade Analytics | Royce Wells | 72.00 % | Subscribe |
| smashingdon | Paul | 70.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
